Editas Medicine (NASDAQ:EDIT)

CAPS Rating: 5 out of 5


How do you think EDIT will perform against the market?

Add Stock to CAPS Watchlist

All Players

222 Outperform
8 Underperform

All-Star Players

70 Outperform
1 Underperform

Wall Street

0 Outperform
0 Underperform

Top EDIT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

rhallbick (95.65)
Submitted April 15, 2018

Editas Medicine (NASDAQ: EDIT) is a biotech specializing in CRISPR-Cas9 research and development. CRISPR has promise for the treatment of patients with genetically defined diseases by correcting their disease?causing genes.CRISPR is an acronym for… More

btechrisk11 (< 20)
Submitted April 15, 2018

Still a lot to learn for CRISPR technology to translate to clinic safely. CRISPR can be fairly selective but there was a recent journal article suggesting many people have antibodies/immune responses against some of the CRISPR elements.


EDIT Summary

Fools bullish on EDIT are also bullish on:

Fools bearish on EDIT are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about EDIT.


Member Avatar future21 (56.67) Submitted: 11/12/2018 4:18:59 PM : Outperform Start Price: $28.49 EDIT Score: -1.06

Promising technology but this is admittedly a bit of a bet... there are no guarantees in biotech. I already picked Intellia, and due to these two companies having the only legitimate claims on patents in this field that I know of (other than Crispr), it only makes sense to take a basket approach with these. Editas is entering preliminary FDA trials. Editas also won the Broad case. It looks to me like Editas is now in the best position to profit from this technology if it proves effective and safe.

As a side note, I have closed my position in CRISPR for now, as it has made gains above and beyond the other two companies without any concrete evidence that it should have, in my opinion. **This is NOT consistent with my general investing strategy, however neither is gambling (more or less) on biotech. My theory behind the rise in CRISPR relative to EDIT and NTLA is that it is identical in name to the technology, and thus likely the first company anyone sees when researching this. For that reason, mixed with the results of the Broad case and the fact that NTLA is working off the same patent family as CRISPR and I've already staked a position in that, it made sense to move forward with EDIT and NTLA as my basket. This 5+ year call comes with the caveat that I'm both a new investor and consider this very risky even as a young investor, and will not be nearly equal in weight to my other positions.

This is essentially a small-stake aimed at diversifying a tech, advertising, and consumer goods heavy portfolio.


Member Avatar apinvest (27.96) Submitted: 9/15/2018 12:38:48 PM : Outperform Start Price: $32.33 EDIT Score: -6.33

CRISPR technology has the potential to revolutionize the treatment of numerous diseases and disorders. EDIT likely holds the rights to some of the earliest foundational patents in this space and is close to entering clinical trials on its first treatments. Some risk here, but huge potential upside justifies it.


Member Avatar Bigsef77 (66.89) Submitted: 9/14/2018 11:09:53 AM : Outperform Start Price: $32.75 EDIT Score: -7.34

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Affirms Favorable U.S. Patent and Trademark Office Decision in CRISPR Interference
GlobeNewswire•September 10, 2018
CAMBRIDGE, Mass., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (EDIT), a leading genome editing company, announced today that the U.S. Court of Appeals for the Federal Circuit (CAFC) affirmed the U.S. Patent and Trademark Office (USPTO) decision that ended the U.S. patent interference between the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively, UC) and the Broad Institute, Inc. (Broad) concerning certain CRISPR/Cas9 patents Editas Medicine exclusively licenses from Broad. This favorable action by the CAFC upholds the USPTO decision issued in February 2017, granting Broad’s motion for no interference-in-fact.

“We are pleased with the Federal Circuit’s decision affirming the Patent Trial and Appeal Board decision on the patents that were granted to the Broad Institute for its innovative and fundamental work on CRISPR/Cas9 genome editing,” said Katrine Bosley, President and Chief Executive Officer, Editas Medicine. “This decision is highly favorable for Editas and for the Broad as it reaffirms the strength of our intellectual property foundation and has profound implications for making CRISPR medicines.”

Editas Medicine’s foundational intellectual property includes issued patents covering fundamental aspects of both CRISPR/Cas9 and CRISPR/Cpf1 (also known as CRISPR/Cas12a) gene editing. The patents broadly cover CRISPR/Cas9 and CRISPR/Cpf1 gene editing in eukaryotic cells, which includes all human cells. Successfully editing this cell type is essential to making CRISPR-based medicines. Overall, the Company holds a wide range of fundamental intellectual property directed to all of the components of its genome editing platform as well as product-enabling and product-specific intellectual property.

In 2014, the USPTO granted the first of several foundational patents to Broad with broad claims covering CRISPR/Cas9 in eukaryotic cells. In 2016, the USPTO declared an interference proceeding between Broad and UC that involved several of Broad’s issued CRISPR patents. While scientists in both groups had made important scientific contributions to the field, this proceeding was initiated by the USPTO to determine which of the two groups first invented the use of CRISPR/Cas9 for editing DNA in eukaryotic cells.

In February 2017, the Patent Trial and Appeal Board of the USPTO determined that the patent claims that had been granted to Broad were separately patentable from, and thus, do not interfere with, the claims of the UC application. This ruling ended the interference proceeding and upheld Broad’s fundamental CRISPR/Cas9 patents as originally granted. Today’s decision affirms that USPTO decision from February 2017. The Broad patents continue to be valid and in force. Foundational claims covering the use of CRISPR/Cas9 for gene editing in eukaryotic cells have also issued to Broad as patents in each of the United States, Europe, and Australia.


Find the members with the highest scoring picks in EDIT.

Score Leader


PAGEBOY73 (99.21) Score: +120.59

The Score Leader is the player with the highest score across all their picks in EDIT.

Member Name Member
Call Time
Score Commentary
SeriousK 28.97 3/9/2016 Underperform 5Y $42.70 -38.38% +27.95% +66.33 0 Comment
freemarketmike < 20 6/7/2017 Outperform 5Y $15.43 +70.48% +4.74% +65.74 1 Comment
WoollyWombat < 20 9/16/2016 Outperform 5Y $14.48 +81.70% +19.55% +62.15 0 Comment
portefeuille 98.36 2/10/2016 Outperform 5Y $13.26 +98.42% +36.79% +61.62 0 Comment
FunesDMemorious 99.29 10/26/2016 Outperform 5Y $14.55 +80.82% +19.64% +61.19 0 Comment
CMFMLove 21.02 6/13/2017 Outperform 5Y $16.00 +64.44% +4.55% +59.89 1 Comment
portefeuille2 98.79 9/22/2016 Outperform 5Y $14.87 +76.93% +17.56% +59.37 0 Comment
Playa14 < 20 6/9/2017 Outperform 5Y $16.08 +63.62% +4.50% +59.12 0 Comment
forcel0 93.65 11/23/2016 Outperform 5Y $15.60 +68.65% +15.92% +52.73 0 Comment
hayrettin 70.49 7/28/2017 Outperform 5Y $16.96 +55.13% +3.41% +51.72 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for EDIT.